A meta-analysis of individual patient data showed that adding hormone therapy to postoperative radiotherapy did not improve overall survival in most men with prostate cancer. The study was presented at a meeting in San Francisco, according to MedPage Today. The analysis included data from six randomized trials. The main finding is that combination therapy did not confer a survival advantage for most patients. The study questions the routine use of hormone therapy in these cases after surgery. The results indicate the need for better selection of patients for such treatment.